PerpEquities

SELLAS Life Sciences Group, Inc. (SLS) financials

NASDAQ · Healthcare · Biotechnology · 13 employees · CEO Angelos Stergiou

Price
$14.69 +2.0%
Market cap
$2.78B
Enterprise value
$2.65B Data as of 2026-11-21
Last report
Q3 '26 filed 2026-11-12
Next report
2027-03-25 EPS est. -$0.05
Revenue (TTM)$0– vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)–– vs a year agoOperating income -$39.4M
Net income (TTM)-$35.8M-37.8% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$27.3M+10.9% vs a year agoCapex $0
Diluted EPS (TTM)-$0.20+31.5% vs a year agoSum of the last 4 quarters
Net cash$134M+206.0% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap
$2.78B
Updated 3h ago
Revenue
$0
Trailing 12 months
Revenue growth
–
FY2026 consensus
Profit margin
–
Net income / revenue, TTM
P/E
No P/E
Loss in the last twelve months
P/S
–
Price / sales, TTM
EV / EBITDA
-74.1×
TTM
Free cash flow
-$27.3M
Trailing 12 months
Net income
-$35.8M
Trailing 12 months
Revenue estimate
$36.1M
FY2026 consensus
Earnings
2027-03-25
Revenue est. $36.1M · Updated 3h ago
Dividend
–
No dividend

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

  • Last report (2026-11-12): revenue n/a, EPS in lineRevenue – vs – expected (–); EPS -$0.05 vs -$0.05 (0.0%).
  • Diluted share count up 86.8% in a year202M diluted shares in Q3 '26, 108M a year earlier.
  • Net cash $134MCash + short-term investments $135M, debt incl. leases $599K; a year ago net cash $43.8M.

Last quarter: Q3 '26

Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

Q3 '26Year agoChange
Revenue$0$0–
Operating income-$11.3M-$7.08M-59.7%
Net income-$10.1M-$6.79M-48.6%
Diluted EPS-$0.05-$0.06+20.1%
Operating cash flow-$5.94M-$7.07M+16.0%
Capex$0$0–
Free cash flow-$5.94M-$7.07M+16.0%
R&D$7.03M$4.22M+66.7%
Stock-based compensation$1.93M$503K+284.1%

Reported vs consensus

2026-11-12
ActualConsensusvs consensus
EPS (as estimated)-$0.05-$0.050.0%

From the report of 2026-11-12 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.

EPS vs consensus

last 8 reports

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement
Operating cash flow
-$27.3M
Capex
$0
Buybacks
$0
Dividends
$0
Acquisitions
$0
Net debt issued
$0
Stock-based compensation
$4.19M
Free cash flow
-$27.3M
Returned to shareholders / FCF
0.0%

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years
Now5y averageWhere today sits in the 5-year range
P/E (TTM)–––
EV / EBITDA-74.1×66.5× 2 of 5 years52.6× – 80.3×
EV / Sales0.0×19.1× 2 of 5 years8.5× – 29.6×
Price / FCF-102.0×––
Price / Book21.0×6.5× 4 of 5 years4.2× – 9.4×
FCF yield-1.0%-56.0%-125.4% – -6.9%
Return on invested capital-29.8%-127.6%-723.3% – 535.6%
Return on equity-31.9%-169.8%-851.4% – 468.2%

Analysts

Consensus target $35.00 (+156.2%)
range $35.00 – $35.00 · rating Buy

Strong buy0
Buy5
Hold0
Sell0
Strong sell0

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal yearRevenueGrowthEPSGrowthP/E at today's priceAnalysts (EPS)
FY2026$36.1M–-$0.20+20.0%–1
FY2027$54.7M+51.3%-$0.25-22.5%–2
FY2028$78.9M+44.3%-$0.02+91.8%–2
FY2029$186M+135.5%$0.36+1,900.0%40.8×1
FY2030$789M+324.6%$2.68+644.4%5.5×1

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Every reported line

All 135 figures SELLAS Life Sciences Group, Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).

Line (SEC label)Latest quarterYear agoy/yLatest FYPrior FYy/y
Accounts Payable, Current$2.09M$2.31M-9.4%$2.95M$3.5M-15.8%
Accrued Liabilities, Current$6.6M$3.02M+118.4%$3.53M$5.47M-35.5%
Accrued Professional Fees, Current$1.28M$224K+471.0%$190K$308K-38.3%
Additional Paid in Capital, Common Stock$435M$313M+39.0%$346M$258M+34.3%
Administrative Fees Expense$300K2026-07-24–––––
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount-1.61M-5.3M+69.7%62M58.3M+6.5%
APIC, Share-based Payment Arrangement, Increase for Cost Recognition$1.93M$503K+284.1%$1.96M$1.56M+25.1%
Assets$141M$51.6M+173.7%$78.3M$19.4M+303.2%
Assets, Current$139M$49.1M+182.5%$75.2M$16.3M+360.7%
Cash and Cash Equivalents, at Carrying Value$135M$44.3M+204.0%$71.8M$13.9M+417.0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents$135M$44.4M+203.5%$71.9M$14M+414.0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect-$3.63M$19M-119.1%$57.9M$11.4M+409.9%
Class of Warrant or Right, Exercise Price of Warrants or Rights$1.69––$0.75––
Class of Warrant or Right, Outstanding8.12M63.7M-87.2%58.5M56M+4.5%
Common Stock, Capital Shares Reserved for Future Issuance33.7M70.2M-51.9%64.2M61.8M+3.9%
Common Stock, Par or Stated Value Per Share$0.00$0.000.0%$0.00$0.000.0%
Common Stock, Shares Authorized350M350M0.0%350M350M0.0%
Common Stock, Shares, Issued204M125M+62.7%153M74M+107.0%
Common Stock, Shares, Outstanding204M125M+62.7%153M74M+107.0%
Common Stock, Value, Issued$20K$12K+66.7%$15K$7K+114.3%
Cost of Goods and Services Sold$0$0–$0$0–
Costs and Expenses$11.3M$7.08M+59.7%$28.3M$31.5M-10.3%
Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction$02026-03-31$21K-100.0%$17K$0–
Decrease in Unrecognized Tax Benefits is Reasonably Possible$02025-12-31––$0––
Deferred Tax Assets, Gross$23M2025-12-31$21.1M+9.4%$23M$21.1M+9.4%
Deferred Tax Assets, in Process Research and Development$2.19M2025-12-31$2.5M-12.7%$2.19M$2.5M-12.7%
Deferred Tax Assets, Net of Valuation Allowance$208K2025-12-31$200K+4.0%$208K$200K+4.0%
Deferred Tax Assets, Operating Loss Carryforwards$16.7M2025-12-31$14.1M+18.5%$16.7M$14.1M+18.5%
Deferred Tax Assets, Other$355K2025-12-31$324K+9.6%$355K$324K+9.6%
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost$797K2025-12-31$622K+28.1%$797K$622K+28.1%
Deferred Tax Assets, Valuation Allowance$22.8M2025-12-31$20.9M+9.5%$22.8M$20.9M+9.5%
Deferred Tax Liabilities, Gross$208K2025-12-31$200K+4.0%$208K$200K+4.0%
Deferred Tax Liabilities, Net$02025-12-31$0–$0$0–
Defined Benefit Plan, Plan Assets, Contributions by Employer–––$117K$124K-5.6%
Deposits Assets, Noncurrent$25K$34K-26.5%$257K$266K-3.4%
Earnings Per Share, Basic-$0.05-$0.06+16.7%-$0.25-$0.50+50.0%
Earnings Per Share, Diluted-$0.05-$0.06+16.7%-$0.25-$0.50+50.0%
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount–––-$5.64M––
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent–––21.0%21.0%0.0%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount–––$1.92M––
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent–––-7.1%-6.6%-7.6%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent–––-14.5%2024-12-31-15.3%+5.2%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount–––$140K––
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent–––-0.5%––
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount–––-$47K––
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent–––0.2%0.2%0.0%
Effective Income Tax Rate Reconciliation, Percent–––0.0%0.0%–
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent–––0.4%2024-12-310.4%0.0%
Employee-related Liabilities, Current$1.57M$1.42M+10.3%$1.75M$1.78M-1.4%
Estimated Litigation Liability, Current$1.02M2026-06-30––$02018-12-31$1.3M-100.0%
Gain (Loss) Related to Litigation Settlement-$1M2026-06-30––-$2.75M2016-12-31-$5.28M+47.9%
General and Administrative Expense$4.28M$2.87M+49.3%$6.59M2012-12-31$8.64M-23.7%
Goodwill$1.91M$1.91M0.0%$1.91M$1.91M0.0%
Goodwill, Impaired, Accumulated Impairment Loss$02025-12-31$0–$0$0–
Goodwill, Impairment Loss–––$0$0–
Income (Loss) from Continuing Operations before Income Taxes, Domestic–––-$9.57M-$9.54M-0.4%
Income (Loss) from Continuing Operations before Income Taxes, Foreign–––-$17.3M-$21.3M+19.0%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest–––-$26.9M-$30.9M+13.0%
Income Tax Expense (Benefit)–––$0$0–
Income Taxes Paid, Net–––$0$0–

Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

Data as of 2026-11-21